CINA CHEST vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CINA CHEST

by Avicenna.AI

EchoNext

by Pathway Labs

AI Verdict

CINA CHEST and EchoNext are both FDA-cleared AI tools focused on cardiovascular health, but they address different diagnostic stages and utilize distinct imaging modalities. CINA CHEST is designed for rapid triage of acute, life-threatening conditions like Pulmonary Embolism and Aortic Dissection using CT angiography scans. In contrast, EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure and valve disease, aiming for earlier detection before symptoms manifest.

Choose CINA CHEST if…

Choose CINA CHEST if your emergency radiology department needs rapid AI-powered triage and notification for life-threatening chest conditions. This tool is ideal for quickly identifying suspected Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans, assisting radiologists in prioritizing urgent cases and accelerating treatment decisions.

View CINA CHEST →

Choose EchoNext if…

Choose EchoNext if your practice aims to leverage standard ECGs for early detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. This AI tool is best suited for broad screening to identify patients who may require further diagnostic imaging like echocardiograms, thereby expanding access to early heart disease screening.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CINA CHEST	EchoNext
Pricing	Subscription-based	Starts at $600/month
Deployment	Cloud-based, On-premise (dedicated hardware), Virtualized (VM, Docker)	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	K210237 AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CINA CHEST

CINA CHEST operates as a standalone web application and provides notifications with compressed preview images, suggesting a user-friendly interface for rapid triage. EchoNext is available through the OpenEvidence clinical decision support platform, which might imply an additional layer of integration or a less direct user experience for some clinicians.

Clinical Value

EchoNext

EchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even those assisted by AI. It was trained on a significantly larger dataset of ECG-echocardiogram pairs and has been credited with leading to a heart transplant, showcasing a direct impact on patient outcomes. CINA CHEST is a triage and notification tool, assisting in workflow prioritization, but its direct impact on diagnostic accuracy compared to human interpretation is not as strongly highlighted in the provided information.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts. CINA CHEST's pricing is subscription-based with details available upon request, which offers less transparency upfront. Therefore, EchoNext offers clearer value proposition with its published pricing structure.

Enterprise Readiness

Tie

Both tools demonstrate enterprise readiness. CINA CHEST offers flexible deployment options (cloud, on-premise, virtualized) and states HIPAA compliance. EchoNext is available through a widely used clinical decision support platform (OpenEvidence) and is also HIPAA compliant, indicating its ability to integrate into existing healthcare IT infrastructures. Both are FDA-cleared, which is a key aspect of enterprise readiness.

Innovation

EchoNext

EchoNext represents a significant innovation by enabling the detection of hidden structural heart disease from standard ECGs, a capability previously not possible with ECGs alone. This has the potential to create an entirely new screening paradigm for heart disease. CINA CHEST, while valuable for rapid triage of life-threatening conditions, is an enhancement of existing imaging interpretation workflows rather than a fundamentally new diagnostic approach.

Support & Docs

Tie

Neither tool provides specific details on their support and documentation offerings in the provided information. Without further details, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CINA CHEST	EchoNext
Tool Name	CINA CHEST	EchoNext
Company	Avicenna.AI	Pathway Labs
Description	FDA-cleared AI-powered radiological triage and notification software by Avicenna.AI, designed for the rapid detection and prioritization of Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Functionality	Radiological computer-aided triage and notification for Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans.	AI-powered ECG analysis for detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

Videos

Demos, reviews, and walkthroughs featuring CINA CHEST and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do CINA CHEST and EchoNext integrate into existing clinical workflows and EHR systems?

CINA CHEST is designed to integrate seamlessly into radiology workflows, operating as a standalone web application that flags suspected positive findings of PE and AD on CT angiography scans and communicates them to radiologists. EchoNext integrates through the OpenEvidence clinical decision support platform, aiming to put its screening output in front of physicians using tools they already utilize at the point of care. Both tools are intended to operate in parallel with standard care, assisting with triage and prioritization without altering original images or disrupting existing interpretation queues.

What are the accuracy and sensitivity of CINA CHEST for PE and AD detection, and EchoNext for structural heart disease?

CINA CHEST for PE has demonstrated a sensitivity of 91.1-91.4% and specificity of 91.5-91.8%. For AD, CINA CHEST has shown an accuracy of 97.89%, sensitivity of 94.29%, and specificity of 100%. EchoNext has shown high accuracy in detecting structural heart disease, outperforming cardiologists in studies, with one study reporting 77% accuracy for EchoNext compared to 64% for cardiologists without AI assistance.

What is the learning curve for physicians using these AI tools, and what kind of support is available?

While specific details on the learning curve for CINA CHEST are not provided, its design as a triage and notification tool integrated into existing radiology workflows suggests it aims for ease of use. Avicenna.AI states its tools are seamlessly integrated within clinical workflow, automatically triggering and reporting results. EchoNext is also designed for broad access and integration into existing physician platforms like OpenEvidence, implying an effort to minimize the learning curve. Both companies likely offer support as part of their subscription models, though specific support quality details are not elaborated in the provided information.

How do these tools support multi-site rollouts and what are the considerations?

CINA CHEST is designed to assist hospital networks in workflow triage, suggesting its suitability for multi-site deployments. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals in studies, indicating its generalizability for multi-site rollouts. Considerations for multi-site rollouts would include ensuring consistent IT infrastructure integration and post-deployment monitoring across all sites.

What audit-trail features are available in CINA CHEST and EchoNext to ensure accountability and transparency?

The provided information does not explicitly detail the audit-trail features for either CINA CHEST or EchoNext. In clinical research and healthcare, audit trails typically track user identification, timestamps of actions, details of changes made to data, and ensure unalterability of these records to promote transparency and accountability.

In what clinical contexts would a physician choose CINA CHEST over EchoNext, or vice versa?

A physician would choose CINA CHEST in an emergency radiology setting for rapid detection and prioritization of life-threatening chest conditions like Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans, where timely triage is critical. Conversely, a physician would choose EchoNext for analyzing standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, particularly for early screening and identifying patients who would benefit from further echocardiogram evaluation.